ARX-517 is under clinical development by Ambrx Biopharma and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ARX-517’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ARX-517 is under development for the treatment of solid tumors including metastatic castration-resistant prostate cancer, pancreatic cancer, non-small lung cancer, ovarian cancer and glioblastoma multiforme. It is administered intravenously. It is an antibody drug conjugate (ADC) targeting prostate specific membrane antigen (PSMA). The drug candidate is based on site-specific conjugation technology using EuCODE mammalian host system.
Ambrx Biopharma overview
Ambrx Biopharma (Ambrx) is a biopharmaceutical company. The company’s pripeline products include anti-HER2 ADC (ARX788), anti-PSMA ADC (ARX517) and anti-CD70 ADC (ARX305). It carries out the research and development of bio-conjugates for animal health, and drugs to treat nonalcoholic steatohepatitis (NASH), heart failure, oncology and immune-oncology diseases. Ambrx creates long acting therapeutic peptides and proteins, modified antibodies and bi-specific fragments through its ReCODE expression system; and larger and complex proteins using its EuCODE expression system. The company works in collaboration with Bristol Myers Squibb, TSRI and Abbvie, Sino Biopharmaceutical, Sino Biopharmaceutical Co Ltd and BeiGene to discover, develop and commercialize antibody-drug conjugates (ADCs). Ambrx is headquartered in La Jolla, California, the US.
For a complete picture of ARX-517’s drug-specific PTSR and LoA scores, buy the report here.